摘要
儿童原发性肾病综合征(PNS)是一种具有挑战性且持续存在的肾脏疾病。糖皮质激素是治疗PNS的一线用药,为减少激素剂量累积带来的副反应以及维持疾病缓解状态,免疫抑制剂被应用到PNS的治疗中,但仍有很多患儿疾病不能获得缓解。利妥昔单抗(RTX)是一种新型的免疫抑制剂,近年来,许多研究对RTX治疗PNS进行了报道。文章主要就该药治疗儿童PNS的机制、疗程与剂量、有效性和安全性进行综述。
Childhood primary nephrotic syndrome(PNS)is a challenging and persistent renal disorder.Corticosteroids is the first-line drug for the treatment of PNS.To reduce the side effects caused by the accumulation of corticosteroids dose and to maintain the remission state of the disease,immunosuppressants are applied to the treatment of PNS.However,many children with PNS still cannot get remission.Rituximab(RTX)is a novel immunosuppressive agent.In recent years,many studies have reported the treatment of PNS in children with RTX.This review analyzes the mechanism,course of treatment,dose,efficacy,and safety of RTX in the treatment of children with PNS.
作者
王美秋(综述)
夏正坤
高春林(审校)
WANG Mei-qiu;XIA Zheng-kun;GAO Chun-lin(Department of Pediatrics,Jinling Hospital,Nanjing School Clinical Medicine,Southern Medical University/General Hospital of Eastern Theater Command,PLA,Nanjing 210002,Jiangsu,China)
出处
《医学研究生学报》
CAS
北大核心
2020年第4期433-437,共5页
Journal of Medical Postgraduates
基金
江苏省重点研发计划-临床前沿技术项目(BE2017719)
江苏省儿科医学创新团队项目(CXTDA2017022)。
